Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmen Belli

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Expert Review of Clinical Pharmacology|September 30, 2021
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directionsMatteo Repetto, Edoardo Crimini, Federica Giugliano, et al.
Investigational New Drugs|May 25, 2022
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046Matteo Repetto, Edoardo Crimini, Liliana Ascione, et al.
Cancers|September 9, 2022
Targeting Cellular Components of the Tumor Microenvironment in Solid MalignanciesCarmen Belli, Gabriele Antonarelli, Matteo Repetto, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2020
Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicityLuca Mazzarella, Silvia Giugliano, Paolo D'Amico, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2019
The evolving landscape of 'next-generation' immune checkpoint inhibitors: A reviewLuca Mazzarella, Bruno Achutti Duso, Dario Trapani, et al.
Journal of Oncology|July 9, 2009
Clinical Significance of Skin Toxicity due to EGFR-Targeted TherapiesMonica Giovannini, Vanesa Gregorc, Carmen Belli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2020
Progresses Toward Precision Medicine in <i>RET</i>-altered Solid TumorsCarmen Belli, Santosh Anand, Justin F Gainor, et al.
Cancer Treatment Reviews|March 5, 2018
Targeting the microenvironment in solid tumorsCarmen Belli, Dario Trapani, Giulia Viale, et al.
Critical Reviews in Oncology/Hematology|November 19, 2018
Liver toxicity in the era of immune checkpoint inhibitors: A practical approachCarmen Belli, Massimo Zuin, Luca Mazzarella, et al.
European Journal of Cancer (Oxford, England : 1990)|July 14, 2023
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing dataMatteo Repetto, Edoardo Crimini, Carmen Belli, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Expert Review of Clinical Pharmacology|September 30, 2021
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directionsMatteo Repetto, Edoardo Crimini, Federica Giugliano, et al.
Investigational New Drugs|May 25, 2022
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046Matteo Repetto, Edoardo Crimini, Liliana Ascione, et al.
Cancers|September 9, 2022
Targeting Cellular Components of the Tumor Microenvironment in Solid MalignanciesCarmen Belli, Gabriele Antonarelli, Matteo Repetto, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2020
Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicityLuca Mazzarella, Silvia Giugliano, Paolo D'Amico, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2019
The evolving landscape of 'next-generation' immune checkpoint inhibitors: A reviewLuca Mazzarella, Bruno Achutti Duso, Dario Trapani, et al.
Journal of Oncology|July 9, 2009
Clinical Significance of Skin Toxicity due to EGFR-Targeted TherapiesMonica Giovannini, Vanesa Gregorc, Carmen Belli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2020
Progresses Toward Precision Medicine in <i>RET</i>-altered Solid TumorsCarmen Belli, Santosh Anand, Justin F Gainor, et al.
Cancer Treatment Reviews|March 5, 2018
Targeting the microenvironment in solid tumorsCarmen Belli, Dario Trapani, Giulia Viale, et al.
Critical Reviews in Oncology/Hematology|November 19, 2018
Liver toxicity in the era of immune checkpoint inhibitors: A practical approachCarmen Belli, Massimo Zuin, Luca Mazzarella, et al.
European Journal of Cancer (Oxford, England : 1990)|July 14, 2023
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing dataMatteo Repetto, Edoardo Crimini, Carmen Belli, et al.
Pageof 5